A5035426042- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Epigenetics and DNA Methylation
- Lymphoma Diagnosis and Treatment
- Cancer-related gene regulation
- RNA modifications and cancer
- Retinoids in leukemia and cellular processes
- Childhood Cancer Survivors' Quality of Life
- Cancer-related molecular mechanisms research
- Advanced biosensing and bioanalysis techniques
- T-cell and Retrovirus Studies
- MicroRNA in disease regulation
- Immune Cell Function and Interaction
- Renal and related cancers
- RNA Interference and Gene Delivery
- Mycobacterium research and diagnosis
University of Lübeck
2019-2025
University Hospital Schleswig-Holstein
2019-2025
Kiel University
2020-2024
Deutsche Forschungsgemeinschaft
2022-2024
Universitätsklinikum Knappschaftskrankenhaus Bochum
2024
Clinical Research Center Kiel
2023
Charité - Universitätsmedizin Berlin
2013-2022
Deutschen Konsortium für Translationale Krebsforschung
2014-2022
German Cancer Research Center
2014-2022
Centre Hospitalier Universitaire de Nantes
2022
A microRNA signature in molecularly defined
To evaluate the prognostic significance of CEBPA mutations in context established molecular markers cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis CN-AML high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence than low-risk (FLT3-ITD negative mutated).
Clinical research relies on high-quality patient data, however, obtaining big data sets is costly and access to existing often hindered by privacy regulatory concerns. Synthetic generation holds the promise of effectively bypassing these boundaries allowing for simplified accessibility prospect synthetic control cohorts. We employed two different methodologies generative artificial intelligence - CTAB-GAN+ normalizing flows (NFlow) synthesize derived from 1606 patients with acute myeloid...
Purpose To analyze the prognostic impact of Wilms’ tumor 1 (WT1) gene mutations in cytogenetically normal acute myeloid leukemia (CN-AML). Patients and Methods We studied 196 adults younger than 60 years with newly diagnosed primary CN-AML, who were treated similarly on Cancer Leukemia Group B (CALGB) protocols 9621 19808, for WT1 exons 7 9. The patients also assessed presence FLT3 internal tandem duplications (FLT3-ITD), tyrosine kinase domain (FLT3-TKD), MLL partial (MLL-PTD), NPM1 CEBPA...
To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML).Pretreatment blood samples from 84 AML patients aged less than 60 years, who were characterized for BAALC expression, FLT3 internal tandem duplication (ITD), and MLL partial (PTD) uniformly treated on Cancer Leukemia Group B 9621 protocol, analyzed ERG by real-time reverse transcriptase polymerase chain reaction. Patients divided into quartiles according to...
To validate ERG overexpression as an adverse predictor and assess its prognostic value in the context of other molecular markers cytogenetically normal (CN) -acute myeloid leukemia (AML).Seventy-six adult patients with primary CN-AML, younger than 60 years treated on Cancer Leukemia Group B (CALGB) trial 19808, were evaluated for expression by quantitative reverse transcriptase polymerase chain reaction. They then combined 72 enrolled onto CALGB 9621 analyses that included markers.Similar to...
Purpose To evaluate the prognostic significance of expression levels a single microRNA, miR-181a, in context established molecular markers cytogenetically normal acute myeloid leukemia (CN-AML), and to gain insight into leukemogenic role miR-181a. Patients Methods miR-181a was measured pretreatment marrow using Ohio State University Comprehensive Cancer Center version 3.0 arrays 187 younger (< 60 years) adults with CN-AML. Presence other prognosticators assessed centrally. A...
Purpose Evaluate the impact of BAALC (brain and acute leukemia, cytoplasmic), a gene whose expression has been associated with adverse outcome in myeloid leukemia (AML) normal cytogenetics, FLT3 internal tandem duplication (ITD) mutations as independent prognostic factors larger study. Patients Methods was determined by real-time reverse transcriptase polymerase chain reaction pretreatment blood samples 307 adults ≤ 60 years age AML cytogenetics. were dichotomized at BAALC's median into low...
PURPOSE To determine the prognostic importance of meningioma 1 (MN1) gene expression levels in context other predictive molecular markers, and to derive MN1 associated gene- microRNA-expression profiles cytogenetically normal acute myeloid leukemia (CN-AML). PATIENTS AND METHODS was measured 119 untreated primary CN-AML adults younger than 60 years by real-time reverse-transcriptase polymerase chain reaction. Patients were also tested for FLT3, NPM1, CEBPA, WT1 mutations, MLL partial tandem...
Philadelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like ALL) is characterized by distinct genetic alterations and inferior prognosis in children younger adults. The purpose of this study was a clinical characterization Ph-like ALL Twenty-six (13%) 207 adult patients (median age: 42 years) with (BCP-ALL) were classified as having using gene expression profiling. frequency 27% among 95 BCP-ALL negative for BCR-ABL1 KMT2A-rearrangements. IGH-CRLF2 rearrangements (6/16; P=0.002)...
A subgroup of pediatric acute T-lymphoblastic leukemia (T-ALL) was characterized by a gene expression profile comparable to that early T-cell precursors (ETPs) with highly unfavorable outcome. We have investigated clinical and molecular characteristics the ETP-ALL in adult T-ALL. As represents T-ALL we particularly focused on this cohort identified 178 patients enrolled German Acute Lymphoblastic Leukemia Multicenter studies (05/93–07/03). Of these, 32% (57/178) were classified as based...